Intratumoral Ipilimumab in Head and Neck Cancer
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Ipilimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 24 Jan 2024 Planned End Date changed from 1 Nov 2023 to 1 Dec 2024.
- 08 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2022 Status changed from not stated to recruiting.